Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities
Christelle Vauloup1, Roman Krzysiek1,2, Liliane Greangeot-Keros1, Daniel Wendling3, Phillippe Goupille4, Rachel Brault5, Christine Brousse6, Xavier Mariette7, Dominique Emilie1,2
European Cytokine Network, Vol.17, No.4, pp. 290-293, 2006, DOI:10.1684/ecn.2006.0046
Abstract Background. Chronic hepatitis C infection is frequently associated with a mixed cryoglobulinaemia
and circulating auto-antibodies, especially anti-smooth muscle cells (SMA) and anti-liver/kidney/microsome type
1 (LKM-1) anti-tissue antibodies. Treatments with TNF antagonists favour the emergence of auto-antibodies, and
particularly anti-dsDNA antibodies. Objective. To determine the impact of TNF antagonists on hepatitis C-related
immune abnormalities. Methods. We prospectively monitored for 14 weeks, six patients with actively replicating
chronic hepatitis C, initiating an anti-TNF treatment for an associated rheumatoid arthritis. Results. Anti-nuclear
and anti-dsDNA antibodies were induced in two and three patients, respectively. Treatment had no impact on More >